CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines

Cancer Research

Volumn 74, Issue 23, 2014, Pages 7103-7114

  Sicoli, Daniela ^a,b,c   Jiao, Xuanmao ^a,b   Ju, Xiaoming ^a,b   Velasco Velazquez, Marco ^a,b,d   Ertel, Adam ^a,b   Addya, Sankar ^a,b   Li, Zhiping ^a,b   Andò, Sebastiano ^c   Fatatis, Alessandro ^b,e   Paudyal, Bishnuhari ^a   Cristofanilli, Massimo ^a,b   Thakur, Mathew L ^a,b   Lisanti, Michael P ^b,f,g   Pestell, Richard G ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF CALABRIA   (Italy)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MARAVIROC; CCR5 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER GROWTH; CCR5 GENE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; IMMUNOCOMPETENCE; IN VIVO STUDY; KIDNEY METASTASIS; LIVER METASTASIS; MALE; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; ONCOGENE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE EPITHELIUM; TREATMENT OUTCOME; TUMOR INVASION; V SRC GENE; ANIMAL; BONE NEOPLASMS; BRAIN NEOPLASMS; DRUG EFFECTS; EPITHELIUM; EPITHELIUM CELL; GENETICS; HUMAN; METABOLISM; ONCOGENE SRC; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; SECONDARY; TRANSFORMED CELL LINE; TUMOR CELL LINE;

ANIMALS; BONE NEOPLASMS; BRAIN NEOPLASMS; CCR5 RECEPTOR ANTAGONISTS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; EPITHELIAL CELLS; EPITHELIUM; GENE EXPRESSION PROFILING; GENES, SRC; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTORS, CCR5; SRC-FAMILY KINASES;

EID: 84918564403     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0612     Document Type: Article

References (41)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 2009;15:3540-9.
3. Fizazi K. The role of Src in prostate cancer. Ann Oncol 2007;18:1765-73.
4. Cai H, Smith DA, Memarzadeh S, Lowell CA, Cooper JA, Witte ON. Differential transformation capacity of Src family kinases during the initiation of prostate cancer. Proc Natl Acad Sci U S A 2011;108:6579-84.
5. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-61.
6. Cai H, Babic I, Wei X, Huang J, Witte ON. Invasive prostate carcinoma driven by c-Src and androgen receptor synergy. Cancer Res 2011;71:862-72.
7. Kraus S, Gioeli D, Vomastek T, Gordon V, Weber MJ. Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. Cancer Res 2006;66:11047-54.
8. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 2000;19:5406-17.
9. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
10. Noguchi M, Kikuchi H, Ishibashi M, Noda S. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer 2003;88:195-201.
11. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64.
12. Fidler IJ. Understanding bone metastases: the key to the effective treatment of prostate cancer. Clin Adv Hematol Oncol 2003;1:278-9.
13. Kim SJ, Uehara H, Yazici S, He J, Langley RR, Mathew P, et al. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res 2005;65:3707-15.
14. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010;24:1967-2000.
15. Irshad S, Abate-Shen C. Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer Metastasis Rev 2013;32:109-22.
16. Ju X, Ertel A, Casimiro MC, Yu Z, Meng H, McCue PA, et al. Novel oncogene-induced metastatic prostate cancer cell lines define human prostate cancer progression signatures. Cancer Res 2013;73:978-89.
17. Liu H, Patel MR, Prescher JA, Patsialou A, Qian D, Lin J, et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci U S A 2010;107:18115-20.
18. Desai B, Rogers MJ, Chellaiah MA. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer 2007;6:18.
19. Bondareva A, Downey CM, Ayres F, Liu W, Boyd SK, Hallgrimsson B, et al. The lysyl oxidase inhibitor, beta-aminopropionitrile, diminishes the metastatic colonization potential of circulating breast cancer cells. PLoS ONE 2009;4:e5620.
20. Jiao X, Katiyar S, Willmarth NE, Liu M, Ma X, Flomenberg N, et al. c-Jun. induces mammary epithelial cellular invasion and breast cancer stem cell expansion. J Biol Chem 2010;285:8218-26.
21. Russell MR, Liu Q, Fatatis A. Targeting the {alpha} receptor for plateletderived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis. Clin Cancer Res 2010;16:5002-10.
22. Power CA, Pwint H, Chan J, Cho J, Yu Y, Walsh W, et al. A novel model of bone-metastatic prostate cancer in immunocompetent mice. Prostate 2009;69:1613-23.
23. Thudi NK, Martin CK, Nadella MV, Fernandez SA, Werbeck JL, Pinzone JJ, et al. Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions. Prostate 2008;68:1116-25.
24. Ralis ZA, Watkins G. Modified tetrachrome method for osteoid and defectively mineralized bone in paraffin sections. Biotech Histochem 1992;67:339-45.
25. Schalken JA, van Leenders G. Cellular and molecular biology of the prostate: stem cell biology. Urology 2003;62:11-20.
26. Velasco-Velazquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, et al. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res 2012;72:3839-50.
27. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003;1:E59.
28. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011;470:269-73.
29. Wang J, Kobayashi T, Floc'h N, Kinkade CW, Aytes A, Dankort D, et al. B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res 2012;72:4765-76.
30. Sethi N, Kang Y. Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer 2011;11:735-48.
31. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
32. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009;459:1005-9.
33. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
34. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000;406:532-5.
35. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-39.
36. Gumireddy K, Sun F, Klein-Szanto AJ, Gibbins JM, Gimotty PA, Saunders AJ, et al. In vivo selection for metastasis promoting genes in the mouse. Proc Natl Acad Sci U S A 2007;104:6696-701.
37. Lee F, Jure-Kunkel MN, Salvati ME. Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence. Ther Adv Med Oncol 2011;3:11-25.
38. Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 2009;48:964-70.
39. Dalton RN, Chetty R, Stuart M, Iacona RB, Swaisland A. Effects of the Src inhibitor saracatinib (AZD0530) on renal function in healthy subjects. Anticancer Res 2010;30:2935-42.
40. Giehl M, Leitner A, Haferlach C, Duesberg P, Hofmann WK, Hofheinz R, et al. Detection of centrosome aberrations in disease-unrelated cells from patients with tumor treated with tyrosine kinase inhibitors. Eur J Haematol 2010;85:139-48.
41. Aleshin A, Finn RS. SRC: a century of science brought to the clinic. Neoplasia 2010;12:599-607.